Media

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

April 8, 2022 | Poster
Single Cell Analysis Shows That Reovirus Immune Priming Changes the Tumor Immune Micro Environment in Multiple Myeloma
Olea, Julian et al, Previously presented at the American Association for Cancer Research Annual Meeting 2022; April 8-13, 2022
April 8, 2022 | Poster
Combination of reovirus (Pelareorep) and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant chemotherapy (temozolomide) for patients with glioblastoma multiforme (GBM): Long term follow up results of the ReoGliophase Ibtrial
Short, Susan, Previously presented at the American Association for Cancer Research Annual Meeting 2022; April 8-13, 2022
January 20, 2022 | Poster
GOBLET: A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic gastrointestinal cancers exploring treatment combinations with pelareorep and atezolizumab
Arnold, Dirk et al, Previously presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 20-22, 2022
December 1, 2021 | Poster
The Clinical Oncolytic Reovirus Formulation Reolysin Synergistically Augments the Anti-Leukemic Activity of Azacitidine
Schwartz, Rayna et al, Previously presented at the 63rd ASH® Annual Meeting and Exposition
December 1, 2021 | Poster
IRENE study: Phase 2 study of Retifanlimab and the oncolytic virus pelareorep in metastatic triple negative breast cancer
George, Mridula et al, Previously presented at the 2021 San Antonio Breast Cancer Symposium®; San Antonio, TX, USA
September 1, 2021 | Poster
Combination treatment with radiotherapy and oncolytic reovirus generates CD8+ T cell infiltration in primary and abscopal tumours in an organoid model of basal-like breast cancer
Singer R et al. Previously presented at The International Conference on Immunotherapy Radiotherapy Combinations
June 1, 2021 | Poster
Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma
Mahalingam D et al. Previously presented at the 2021 ASCO Annual Meeting
April 10, 2021 | Poster
Talazoparib interacts with oncolytic reovirus to enhance death-inducing signaling complex (DISC)-mediated apoptosis and immune response
Kyula J et al. In: AACR Virtual Annual Meeting 2021; 2021 Apr 10-15; Virtual. AACR; 2021. Abstract 1932
April 10, 2021 | Poster
A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (AWARE-1)
Manso L et al. In: AACR Virtual Annual Meeting 2021; 2021 Apr 10-15; Virtual. AACR; 2021. Abstract CT191
April 10, 2021 | Poster
Mechanisms of therapeutic synergy between pattern recognition response agonists and CDK4 inhibitors
Roulstone V et al. In: AACR Virtual Annual Meeting 2021; 2021 Apr 10-15; Virtual. AACR; 2021. Abstract 1960
February 1, 2021 | Poster
Combination Therapy with Oncolytic Viruses and CAR T Cells
Kottke et al, Previously presented at CAR-TCR Summit Europe 2021
December 9, 2020 | Poster
A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1)
Manso et al, Previously presented at the 2020 Virtual San Antonio Breast Cancer Symposium® - 43rd Annual Meeting;  San Antonio, TX, USA; December 9-11, 2020
December 9, 2020 | Poster
BRACELET-1 (PrE0113): A study to assess overall response rate by inducing an inflammatory phenotype in metastatic breast cancer with the oncolytic reovirus pelareorep in combination with anti-PD-L1 avelumab and paclitaxel
Miller et al, Previously presented at the 2020 Virtual San Antonio Breast Cancer Symposium® - 43rd Annual Meeting;  San Antonio, TX, USA; December 9-11, 2020
December 9, 2020 | Poster
IRENE study: Phase 2 study of INCMGA00012 (retifanlimab) and the oncolytic virus pelareorep in metastatic triple negative breast cancer
George et al, Previously presented at the 2020 Virtual San Antonio Breast Cancer Symposium® - 43rd Annual Meeting;  San Antonio, TX, USA; December 9-11, 2020
November 1, 2020 | Poster
Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer
Prat et al, SITC, 2020

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch